Latest Health News

Associate Global Partners Limited reported a 4.6% increase in funds under management to $1.464 billion for Q3 2025, driven by robust inflows and standout returns from its WCM strategies. The company also sustained positive operating cash flows for the fourth consecutive quarter.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Mont Royal Resources has completed a transformative merger with Commerce Resources, securing A$10 million to advance the Ashram Rare Earths Project, positioning itself as a key player in North America’s critical minerals sector.

Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Tyranna Resources has advanced its exploration and acquisition efforts in Angola, securing a major stake in the Chinguar Gold Project and extending its lithium-caesium project tenure, supported by a solid cash position.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Minerals 260 Limited has expanded its Bullabulling Gold Project drilling program to 110,000 meters following strong high-grade gold intercepts, with an updated resource estimate due in December 2025. Initial metallurgical tests show gold recoveries exceeding 95%, bolstering project economics as the pre-feasibility study advances.

Alcoa Corporation reported a net income of $232 million for Q3 2025, driven by strategic asset sales and operational milestones including the permanent closure of its Kwinana alumina refinery and the sale of its Saudi Arabia joint venture stake.